Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Gossamer Bio Inc
GOSS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$10.16
0.58
6.1%
Ult. Agg.: Oct 21, 1:26 PM
$9.50
-0.08
-0.84%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Gossamer Bio Financials
Gossamer Bio (GOSS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q4 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.799M Beat $7.522M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 14.13 percent. This is a 40 percent decrease over losses of $(0.15) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $13.294M
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.02 percent. This is a 50 percent decrease over losses of $(0.14) per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $11.49M Beat $4.34M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.03 percent. This is a 177.27 percent decrease over earnings of $0.22 per share from the
Benzinga Newsdesk
PRO
Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the
Benzinga Newsdesk
